Recursion uses artificial intelligence to help advance drug discovery, which could be a massive opportunity in healthcare.

Now, it’s worth noting Stock Advisor’s total average return is 1,033% — a market-crushing outperformance compared to 193 % ...

The growth for Vertex’s Journavax painkiller is just beginning to ramp up, given the potential size of the nonaddictive drug ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

Shares of Corbus Pharmaceuticals slid after the company priced its public offering at $13 a share. The stock declined 24% to $12.49 on Friday. Shares are down 22% in the past 12 months.

These companies are investing heavily into their pipelines and the payoff for long-term investors can be substantial.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most profitable biotech stocks to buy. Wells Fargo maintained a Buy ...

BioMarin Pharmaceutical (NASDAQ: BMRN) reported its third-quarter earnings after market close Monday, and they were good ...

Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks.

Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 ...

Genmab A/S (NASDAQ: GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju ...

and NDT Pharmaceuticals Inc. (OTC:NDTP) on the RedChip Small Stocks, Big Money ™ show, a sponsored program on Bloomberg TV ...